Brief communication
Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas

https://doi.org/10.1016/0360-3016(95)00087-FGet rights and content

Abstract

Purpose: To evaluate the efficacy and toxicity of a stereotactic radiosurgery boost as part of the primary management of a minimally selected population of patients with malignant gliomas.

Methods and Materials: Between June, 1991 and January, 1994 a stereotactic radiosurgery boost was given to 30 patients after completion of fractionated external beam radiotherapy. The study population consisted of 22 males and 8 females, with a ranged in age at treatment from 5 to 74 years (median: 54 years). Tumor volume ranged from 2.1 to 115.5 cubic centimeters (cc) (median: 24 cc). Histology included 17 with glioblastoma multiforme, 10 with anaplastic astrocytoma, 1 with a mixed anaplastic astrocytoma-oligodendroglioma, and 2 with a gliosarcoma. A complete resection was performed in 9 (30%) patients, while 18 (60%) underwent a subtotal resection, and 3 (10%) received a biopsy only. Fractionated radiation dose ranged from 44 to 62 Gy, with a median of 59.4 Gy. Prescribed stereotactic radiosurgery dose ranged from 0.5 to 18 Gy (median: 10 Gy), and the volume receiving the prescription dose ranged from 2.1 to 158.7 cc (median: 46 cc). The volume of tumor receiving the prescription dose ranged from 70–100% (median: 100%). One to four (median: 2) isocenters were used, and collimator size ranged from 12.5 to 50 mm (median size: 32.5 mm). The median minimum stereotactic radiosurgery dose was 70% of the prescription dose and the median maximum dose was 200% of the prescription dose.

Results: With a minimum follow-up of 1 year from radiosurgery, 7 (23%) of the patients are still living and 22 (73%)_have died of progressive disease. One patient died of a myocardial infarction 5 months after stereotactic radiosurgery. Follow-up for living patients ranged from 12 to 45 months, with a median of 30 months. The 1- and 2-year disease-specific survival from the date of diagnosis is 57 [95% confidence interval (CI) 39 to 74%] and 25% (95% CI 9 to 41%), respectively (median survival: 13.9 months). No significant acute or late toxicity has been observed.

Conclusions: Stereotactic radiosurgery provides a safe and feasible technique for dose escalation in the primary management of unselected malignant gliomas. Longer follow-up and a randomized prospective trial is required to more thoroughly evaluate the role of radiosurgery in the primary management of malignant gliomas.

References (29)

  • B. Stea et al.

    Treatment of malignant gliomas with interstitial irradiation and hyperthermia

    Int. J. Radiat. Oncol. Biol. Phys.

    (1992)
  • K.E. Wallner et al.

    Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma

    Int. J. Radiat. Oncol. Biol. Phys.

    (1989)
  • C.H. Chang et al.

    Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

    Cancer

    (1983)
  • W.J. Curran et al.

    Survival comparison of radiosurgery-eligible and ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: A report of Radiation Therapy Oncology Group 83-02

    J. Clin. Oncol.

    (1993)
  • Cited by (74)

    • Applications of Stereotactic Radiosurgery in Neuro-Oncology

      2016, Handbook of Neuro-Oncology Neuroimaging: Second Edition
    • Stereotactic Radiosurgery for Intracranial Gliomas

      2013, Neurosurgery Clinics of North America
      Citation Excerpt :

      Although some reports argue for up-dosing fractionated radiotherapy,4 most reports would favor for a boost with SRS, trying to minimize radiation injury to the adjacent normal brain. Historically, many retrospective studies claimed feasibility and apparent efficacy of the combined radiation,5–8 which was supported by some,9,10 but not all,8,11 prospective studies. A prospective study conducted by Mehta and colleagues10 reported a 2-year survival rate of 28% in 31 patients with newly diagnosed glioblastoma treated with the conventional radiotherapy with an SRS boost, which was significantly superior to 9.7% in the previous Radiation Therapy Oncology Group (RTOG) study patients.

    • Secondary gliosarcoma with extra-cranial metastases: A report and review of the literature

      2013, Clinical Neurology and Neurosurgery
      Citation Excerpt :

      It allows additional radiotherapy for many patients who have already completed external beam radiotherapy in the past. Further study is still required to determine the exact role for stereotactic radiosurgery in the treatment of gliosarcoma [27,30]. Little is known about the response of metastatic GS to a traditional sarcoma-based chemotherapeutic regimen including an anthracycline.

    • Decision making and management of gliomas: Practical considerations

      2012, Annals of Oncology
      Citation Excerpt :

      Several uncontrolled retrospective and prospective studies suggested improved survival when a SRS-boost was added to the conventional radiotherapy in newly diagnosed gliomas [53–57]. These data could, however, not be confirmed by other studies [58]. In a prospective multi-institutional, phase III randomized trial (RTOG 93-05), SRS was added to standard external beam RT and carmustine chemotherapy [59].

    View all citing articles on Scopus
    View full text